Humacyte Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Humacyte wird ein Gewinn- und Umsatzwachstum von 46.7% bzw. 60.7% pro Jahr prognostiziert, während der Gewinn pro Aktie um 49.6% pro Jahr wachsen soll.

Wichtige Informationen

46.7%

Wachstumsrate der Gewinne

49.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.2%
Wachstumsrate der Einnahmen	60.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	26 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Jun 05

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

May 14

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:HUMA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	92	-50	-29	-28	5
12/31/2025	30	-98	-60	-83	6
12/31/2024	3	-113	-81	-106	6
3/31/2024	N/A	-106	-84	-82	N/A
12/31/2023	N/A	-111	-76	-73	N/A
9/30/2023	N/A	-89	-76	-73	N/A
6/30/2023	0	-89	-80	-77	N/A
3/31/2023	1	-29	-73	-71	N/A
12/31/2022	2	-12	-72	-71	N/A
9/30/2022	2	34	-74	-74	N/A
6/30/2022	2	28	-88	-87	N/A
3/31/2022	1	-26	-86	-85	N/A
12/31/2021	1	-26	-81	-81	N/A
9/30/2021	1	-85	-75	-75	N/A
6/30/2021	2	-71	-57	-57	N/A
3/31/2021	1	-69	-54	-54	N/A
12/31/2020	1	-67	-56	-56	N/A
12/31/2019	6	-85	-80	-72	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: HUMA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: HUMA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: HUMA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: HUMADie Einnahmen des Unternehmens (60.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: HUMADie Einnahmen des Unternehmens (60.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von HUMA in 3 Jahren voraussichtlich hoch sein wird

Humacyte Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target increased by 7.1% to US$7.50

Consensus revenue estimates decrease by 12%

Consensus revenue estimates fall by 33%

Price target decreased by 24% to US$7.35

Consensus revenue estimates decrease by 45%, EPS upgraded

Recent updates

Humacyte, Inc. Presents Positive Preclinical Data for Its Biovascular Pancreas (Bvp™?) Program

Independent Chairman of the Board exercised options to buy US$234k worth of stock.

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Chief Operating Officer recently sold US$502k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director recently bought US$668k worth of stock

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

Humacyte, Inc. to Report Q1, 2024 Results on May 10, 2024

Humacyte, Inc., Annual General Meeting, Jun 11, 2024

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target increased by 7.1% to US$7.50

New major risk - Revenue and earnings growth

Humacyte, Inc. to Report Q4, 2023 Results on Mar 22, 2024

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.

New minor risk - Shareholder dilution

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Humacyte, Inc. Announces U.S. Food and Drug Administration Accepts and Grants Priority Review to Humacyte's Biologics License Application

New minor risk - Share price stability

Consensus revenue estimates decrease by 12%

Humacyte, Inc. Submits Biologics License Application to U.S. Food and Drug Administration Seeking Approval of Human Acellular Vessel (Hav) for the Treatment of Vascular Trauma

Humacyte, Inc. Announces Presentations of Positive Clinical Results of the Human Acellular Vessel™? (HAV™?) in the Treatment of Vascular Trauma

Humacyte, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Humacyte, Inc. Publishes Preclinical Results Showing Human Acellular Vessel™? Patency as Modified Blalock-Taussig-Thomas Shunt in Juvenile Primate Model

Founder exercised options to buy US$280k worth of stock.

Humacyte, Inc. Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™? (HAV™?) in Treatment of Patients with Vascular Trauma

Humacyte, Inc. Announces the Presentation of Results from FDA Regulated, Investigator-Sponsored Clinical Study Conducted At the Mayo Clinic

Consensus revenue estimates fall by 33%

Humacyte, Inc. Presents Clinical Performance of Human Acellular Vessel (HAV) from Ukrainian Humanitarian Program

New major risk - Revenue size

First half 2023 earnings released: US$0.58 loss per share (vs US$0.17 profit in 1H 2022)

Humacyte, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Humacyte, Inc. Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel

Humacyte, Inc. Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel(Tm) (Hav(Tm)) for Vascular Trauma Repair

Chief Operating Officer exercised options to buy US$240k worth of stock.

First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.19 loss in 1Q 2022)

Humacyte, Inc. to Report Q1, 2023 Results on May 12, 2023

Price target decreased by 24% to US$7.35

Consensus revenue estimates decrease by 45%, EPS upgraded

Price target decreased by 15% to US$9.46

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 16%

Founder exercised options to buy US$321k worth of stock.

Investor sentiment improves as stock rises 15%

Humacyte, Inc. Announces Publication of 6-Year Outcomes of Phase 2 Study of Human-Tissue Engineered Blood Vessels for Peripheral Arterial Bypass, in Journal of Vascular Surgery – Vascular Science

Key Executive recently bought US$52k worth of stock

Investor sentiment deteriorated over the past week

Consensus EPS estimates fall by 13%

High number of new directors

Price target decreased to US$10.13

Consensus EPS estimates fall by 12%

Humacyte, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Humacyte: Intriguing Potential

Humacyte, Inc. Announces New Board Appointments

Investor sentiment improved over the past week

Independent Director recently bought US$193k worth of stock

Investor sentiment deteriorated over the past week

Consensus revenue estimates increase by 126%

Price target decreased to US$11.25

Second quarter 2022 earnings released: EPS: US$0.36 (vs US$0.76 loss in 2Q 2021)

Humacyte GAAP EPS of $0.35, revenue of $1.3M

Humacyte, Inc. to Report Q2, 2022 Results on Aug 12, 2022

High number of new directors

Humacyte, Inc. Announces Results Evaluating the Use of the Small-Diameter (3.5mm) Human Acellular Vessel for Coronary Artery Bypass Grafting in a Non-Human Primate Model

High number of new directors

Humacyte, Inc. Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel(TM) (HAV(TM)) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options

Humacyte, Inc. Appoints Diane Seimetz to its Board of Directors

Humacyte, Inc. Presents New Immunogenicity Data on Human Acellular Vessels(Tm) (Havs(Tm))

First quarter 2022 earnings: EPS and revenues exceed analyst expectations